2023-503594-38-00招募中1 期
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 44
- 试验地点
- 24
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Global Clinical Trials Helpdesk
Scientific
Abbvie Deutschland GmbH & Co. KG
研究点 (24)
Loading locations...
相似试验
招募中
不适用
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants with Moderately to Severely Active Ulcerative Colitis.Ulcerative ColitisjRCT2011230031AbbVie G.K.110
招募中
2 期
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's DiseaseJPRN-jRCT2071230035Otani Tetsuya240
招募中
1 期
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma2024-512586-13-00AbbVie Deutschland GmbH & Co. KG56
暂停
不适用
A Study to Assess Adverse Events and Disease Activity with Cedirogant (ABBV-157) in Adult Participants with
Moderate to Severe PsoriasisjRCT2061210069AbbVie G.K.200
招募中
不适用
[M16-194] A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseCrohn's diseasejRCT2031240708AbbVie G.K.110